| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Chronic hepatitis C: This and the new era of treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Maria Irene Ruggeri, Laura Scuderi, Giulia Malaguarnera, Nicoletta Bertino, Venerando Rapisarda, Isidoro Di Carlo, Adriana Toro, Federico Salomone, Mariano Malaguarnera, Emanuele Bertino and Michele Malaguarnera |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gaetano Bertino, Professor, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, Policlinic - Via S. Sofia n. 78, 95123 Catania, Italy. gaetanobertinounict@libero.it
|
| Key Words |
Direct-acting antiviral agents; Nucleoside inhibitors; Boceprevir; Sofosbuvir; Telaprevir; Hepatitis C; Simeprevir; Daclatasvir; Ledipasvir; Faldaprevir; Ritonavir; Ombitasvir; Dasabuvir |
| Core Tip |
This review analyzes the current therapies for chronic hepatitis C and the future challenges of the research. So it tries to give an update on the research of hepatitis C virus (HCV) infection, providing a critical view of the emerging therapies and their impact on the future management of HCV infection. Since novel treatments for HCV infection are highly efficacious but costly, priority should be given to patients with advanced hepatic fibrosis, which is a disease that cannot be deferred.
|
| Publish Date |
2016-01-15 09:49 |
| Citation |
Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol 2016; 8(2): 92-106 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i2/92.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i2.92 |
